Last updated: 4 months ago
Sanofi's January 2025 Form 6-K: Key Advances in Multiple Myeloma Treatments
Explore Sanofi's January 2025 Form 6-K report detailing positive Sarclisa trial results and its first approval in China, enhancing its oncology portfolio and market presence.